JP2023501347A5 - - Google Patents
Info
- Publication number
- JP2023501347A5 JP2023501347A5 JP2022526035A JP2022526035A JP2023501347A5 JP 2023501347 A5 JP2023501347 A5 JP 2023501347A5 JP 2022526035 A JP2022526035 A JP 2022526035A JP 2022526035 A JP2022526035 A JP 2022526035A JP 2023501347 A5 JP2023501347 A5 JP 2023501347A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antisense oligomer
- fcεriβ
- exon
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932664P | 2019-11-08 | 2019-11-08 | |
| US62/932,664 | 2019-11-08 | ||
| PCT/US2020/059682 WO2021092562A1 (en) | 2019-11-08 | 2020-11-09 | Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501347A JP2023501347A (ja) | 2023-01-18 |
| JP2023501347A5 true JP2023501347A5 (cg-RX-API-DMAC10.html) | 2023-11-16 |
Family
ID=75849333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526035A Pending JP2023501347A (ja) | 2019-11-08 | 2020-11-09 | アレルギー性疾患を治療するためのFcεRIβ及びMS4A6Aを組み合わせたエクソンスキップ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12637677B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4054639A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023501347A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115335078A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020378207A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021092562A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017136435A1 (en) | 2016-02-01 | 2017-08-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof |
| CN112023062A (zh) * | 2020-09-18 | 2020-12-04 | 北京基因安科技有限公司 | 一个用可溶性IgE受体抑制过敏反应的方法 |
| JP2025531483A (ja) * | 2022-09-28 | 2025-09-19 | アタランタ セラピューティクス,インコーポレーテッド | 神経炎症疾患の治療のための組成物及び方法 |
| CN116219009B (zh) * | 2022-10-19 | 2024-10-01 | 杭州师范大学 | 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989849A (en) | 1991-05-09 | 1999-11-23 | Temple University Of The Commonwealth System Of Higher Education | Antisense of oligonucleotides to c-kit proto-oncogene and in vitro methods |
| US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| US20040137566A1 (en) * | 2001-12-10 | 2004-07-15 | Tedder Thomas F. | Identification of novel ms4a gene family members expressed by hematopoietic cells |
| AU2005214287A1 (en) | 2004-02-20 | 2005-09-01 | Genesis Research And Development Corporation Limited | Targeted delivery of RNA interference molecules for the treatment of IgE-mediated disorders |
| WO2005085443A2 (en) | 2004-03-01 | 2005-09-15 | Massachusetts Institute Of Technology | Rnai-based therapeutics for allergic rhinitis and asthma |
| ES2627917T3 (es) | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| EP2290088A1 (en) | 2004-12-22 | 2011-03-02 | Genentech, Inc. | Methods for producing soluble multi-menbrane-spanning proteins |
| WO2007028065A2 (en) | 2005-08-30 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| EP1857548A1 (en) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| WO2009008727A2 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
| US8236557B2 (en) | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| AU2010335039B2 (en) | 2009-12-24 | 2015-03-26 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Molecule for treating an inflammatory disorder |
| ES2566553T3 (es) | 2010-03-17 | 2016-04-13 | Association Institut De Myologie | ARNnp U7 modificados para el tratamiento de las enfermedades neuromusculares |
| EP3023496B1 (en) | 2010-05-13 | 2020-07-29 | Sarepta Therapeutics, Inc. | Compounds which modulate interleukins 17 and 23 signaling activity |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| US20140080896A1 (en) | 2011-08-30 | 2014-03-20 | The Regents Of The University Of California | Identification of small molecules that facilitate therapeutic exon skipping |
| DK2581448T3 (en) | 2011-10-13 | 2015-04-27 | Ass Inst De Myologie | Tricyclo-DNA phosphorothioate |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| CN103074422A (zh) * | 2012-12-29 | 2013-05-01 | 深圳市第三人民医院 | Ms4a6a基因的用途 |
| US9862945B2 (en) | 2013-04-20 | 2018-01-09 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs |
| CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
| WO2016009487A1 (ja) | 2014-07-14 | 2016-01-21 | 三菱電機株式会社 | 空気調和装置 |
| EP3174981B1 (en) | 2014-07-31 | 2020-03-25 | Association Institut de Myologie | Treatment of amyotrophic lateral sclerosis |
| EP2985343A1 (en) | 2014-08-11 | 2016-02-17 | Karlsruher Institut für Technologie | In vitro-co-culturesystem |
| WO2017136435A1 (en) | 2016-02-01 | 2017-08-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof |
| CN105969901B (zh) * | 2016-07-27 | 2019-10-11 | 北京泱深生物信息技术有限公司 | Ms4a6a作为多发性骨髓瘤诊治标志物的用途 |
| WO2019200383A1 (en) * | 2018-04-13 | 2019-10-17 | Ohio State Innovation Foundation | Reagents and methods for autism and comorbidities thereof |
| EP3844278A4 (en) | 2018-08-27 | 2022-05-25 | North Carolina State University | TARGETING KIT WITH SPLICE-SWITCHING OLIGONUCLEOTIDES FOR INDUCING APOPTOSIS OF MASTS CELLS |
-
2020
- 2020-11-09 EP EP20885567.6A patent/EP4054639A4/en active Pending
- 2020-11-09 JP JP2022526035A patent/JP2023501347A/ja active Pending
- 2020-11-09 WO PCT/US2020/059682 patent/WO2021092562A1/en not_active Ceased
- 2020-11-09 AU AU2020378207A patent/AU2020378207A1/en active Pending
- 2020-11-09 US US17/775,136 patent/US12637677B2/en active Active
- 2020-11-09 CN CN202080092446.5A patent/CN115335078A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200291407A1 (en) | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf | |
| AU2018318135B2 (en) | Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA) | |
| US8946183B2 (en) | Compositions and methods for modulation of SMN2 splicing | |
| JP2022523302A (ja) | アッシャー症候群の処置のためのrna編集オリゴヌクレオチド | |
| ES2600356T3 (es) | Tratamiento de enfermedades relacionadas con pirrolin-5-carboxilato reductasa 1 (PYCR1) por inhibición de transcrito antisentido natural para PYCR1 | |
| BR112020007881A2 (pt) | Oligômeros anti-senso para o tratamento de condições e doenças baseadas no decaimento de rna mediado por nonsense | |
| TW201210611A (en) | Treatment of Nicotinamide Phosphoribosyltransferase (NAMPT) related diseases by inhibition of natural antisense transcript to NAMPT | |
| JPH09510714A (ja) | オリゴヌクレオチドn3’→p5’ホスホルアミデート:合成および化合物;ハイブリダイゼーションおよびヌクレアーゼ耐性特性 | |
| KR20080031164A (ko) | SR 단백질의 결합의 방해에 의해 그리고 이차 RNA구조의 방해에 의한 pre-mRNA에서 엑손 인식의조절 | |
| JP2024537991A5 (cg-RX-API-DMAC10.html) | ||
| JP2019500347A5 (cg-RX-API-DMAC10.html) | ||
| TW201219569A (en) | Treatment of Sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 | |
| CA2785727A1 (en) | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) | |
| WO2010120969A1 (en) | Targeting of the mir-30 family and let-7 family as a treatment for heart disease | |
| TW201209163A (en) | Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3 | |
| Slavov et al. | Phylogenetic comparison of the pre-mRNA adenosine deaminase ADAR2 genes and transcripts: conservation and diversity in editing site sequence and alternative splicing patterns | |
| JP2021534799A5 (cg-RX-API-DMAC10.html) | ||
| JP2023542889A5 (cg-RX-API-DMAC10.html) | ||
| US20260035694A1 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| US12529057B2 (en) | Therapeutics for Syngap haploinsufficiency | |
| CN115103911A (zh) | 修饰的异源核酸 | |
| JP2024524974A5 (cg-RX-API-DMAC10.html) | ||
| JPH09501057A (ja) | 新規のオリゴヌクレオチド相互作用による血管細胞接着分子の発現の調節 | |
| JP2022546408A5 (cg-RX-API-DMAC10.html) | ||
| Soldà et al. | In vivo RNA–RNA duplexes from human α3 and α5 nicotinic receptor subunit mRNAs |